<DOC>
	<DOCNO>NCT00368134</DOCNO>
	<brief_summary>This study design evaluate efficacy , safety tolerability vildagliptin compare voglibose patient type 2 diabetes . Please note study conduct United States .</brief_summary>
	<brief_title>To Compare Efficacy Safey Vildagliptin Compared Voglibose Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<criteria>Diagnosis Type 2 Diabetes Patients place dietary therapy/exercise therapy , without achievement glycemic control Outpatients Type 1 diabetes mellitus , diabetes result pancreatic injury , secondary form diabetes Significant heart diseases Significant diabetic complication Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>HbA1c</keyword>
</DOC>